MedTrace Logo

Cholecalciferol Supplementation in Hemodialysis Patients

NCT05922696 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-06-28

No results posted yet for this study

Summary

This is prospective single-blind randomized study, in Ain Shams University hospital) in Egypt, to assess the impact of Cholecalciferol on Anemia status in regular hemodialysis outpatients

Conditions

  • Anemia
  • Hemodialysis Complication
  • Vitamin D Deficiency

Interventions

DRUG

Cholecalciferol

50.000IU weekly in Group A , or 200.000IU monthly in Group B

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-15
Primary Completion
2022-09-15
Completion
2023-01-26

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05922696 on ClinicalTrials.gov